Cabazitaxel — Drug Intelligence | 11 EU Trials

Filter these 11 trials by condition, phase, country and more.

Open in Search →

11 Registered trials

7 Recruiting

4 Completed trials

10 Sponsors

13 Countries

Phase III

Phase II

Phase III: 5 Phase II: 5 Phase I/II: 1

Indications tested

Prostate cancer 3 Prostate cancer metastatic 2 Neuroendocrine carcinoma of prostate 1

Sponsors using this IMP

Amgen Inc. 2 Bristol Myers Squibb International Corporation 1 Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) 1 Fundación Oncosur 1 Karolinska Institutet 1 Novartis Pharma AG 1 Rigshospitalet 1 Swiss Group for Clinical Cancer Research 1 Unicancer 1 UZ Leuven 1

All trials

11 total

A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped respon… Recruiting

2025-521880-10-00 Phase I/II 6 countries Novartis Pharma AG
Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Recruiting

2025-520555-89-00 Phase III 9 countries Amgen Inc.
SAKK 08/23: Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial Recruiting

2024-512132-29-00 Phase II 1 country Swiss Group for Clinical Cancer Research
DAROTAXEL Recruiting

2024-516939-28-00 Phase II 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Ebastine in combination with docetaxel or as a treatment for metastatic castration-resistant prostate cancer Recruiting

2024-518035-11-01 Phase II 1 country Rigshospitalet
Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressiv… Recruiting

2022-502254-13-00 Phase III 1 country UZ Leuven
ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer Recruiting

2023-506857-40-00 Phase III 3 countries Karolinska Institutet
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration-… Ended

2024-513968-25-00 Phase III 11 countries Amgen Inc.
A Phase 2 clinical trial of Pembrolizumab in combination with Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resist… Ended

2022-501139-17-01 Phase II 1 country Fundación Oncosur
A large-scale comparative study evaluating an intravenous treatment, cabazitaxel, and radiation therapy to the pelvic lymph nodes in patient… Ended

2024-517622-25-00 Phase III 3 countries Unicancer
Study of Nivolumab plus Ipilimumab, Ipilimumab or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer Ended

2022-502909-15-00 Phase II 1 country Bristol Myers Squibb International Corporation

Showing 1–11 of 11 trials

← All drugs A–Z